A well-controlled, multicenter study suggests efficacy of paroxetine and venlafaxine.
Single-center treatment studies of depressed patients with Parkinson disease (PD) have shown efficacy for cognitive-behavioral therapy (JW Psychiatry Aug 1 2011) and nortriptyline (JW Psychiatry Feb 9 2009). In this multicenter, 12-week study, researchers randomized 115 patients with PD and major depression, dysthymia, or subsyndromal depression (17-item Hamilton Rating Scale for Depression [HRSD] score, >12), but not dementia, to paroxetine, extended-release venlafaxine, or placebo. Doses initially were 10 mg paroxetine or 37.5 mg venlafaxine and then titrated upward (maximum dose: paroxetine, 40 mg; venlafaxine, 225 mg). Medications were manufacturer-supplied.
Most subjects had major depression (63%; mean HRSD, 21.6). Approximately 90% had…
Reviewing Author
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)
DisclosuresRoyaltiesTextbook of Traumatic Brain Injury, 2nd and 3rd editions
Editorial BoardsUpToDate; Journal of Neuropsychiatry and Clinical Neuroscience
Leadership Positions in Professional SocietiesNorth American Brain Injury Association (Board Member); National Institute on Disability, Independent Living, and Rehabilitation Research (Chair of Data Monitoring Safety Board for study of donepezil on cognition after traumatic brain injury)